Maravai Lifesciences Holdings (MRVI) Gross Profit (2020 - 2026)

Maravai Lifesciences Holdings' Gross Profit history runs 7 years deep, the most recent figure standing at $33.7 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 336.26% year-over-year to $33.7 million in Q1 2026; TTM through Mar 2026 was $60.0 million, a 33.51% decrease from a year earlier, with the FY2025 full-year figure at $34.0 million, down 68.62% from the prior year.
• Gross Profit rose to $33.7 million in Q1 2026 per MRVI's latest filing, from $12.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $205.2 million in Q2 2022 and bottomed at $5.7 million in Q3 2025.
• The 5-year median for Gross Profit is $30.8 million (2024), against an average of $60.6 million.
• Across the five-year window, Gross Profit sank 87.51% in 2023 and surged 336.26% in 2026, its largest moves.
• Year by year, Gross Profit stood at $151.5 million in 2022, then plunged by 74.23% to $39.0 million in 2023, then slumped by 50.32% to $19.4 million in 2024, then tumbled by 33.77% to $12.8 million in 2025, then surged by 162.43% to $33.7 million in 2026.
• Per Business Quant, the three latest MRVI Gross Profit figures stand at $33.7 million (Q1 2026), $12.8 million (Q4 2025), and $5.7 million (Q3 2025).